Revolutionary therapy: higher chances of children after Hodgkin lymphoma!

Revolutionary therapy: higher chances of children after Hodgkin lymphoma!

Köln, Deutschland - In Cologne there are gratifying news for young patients who are ill with advanced Hodgkin lymphoma. An international study under the direction of the German Hodgkin Study Group (GHSG) at the University Hospital Cologne shows that the new therapy approaches significantly improve the chances of their own family after treatment. The new chemotherapy BRECADD in particular seems to be a real ray of hope in this regard. According to [uk-koeln.de] (https://www.uk-koeln.de/uniklinik-koeln/aktuelles/detailsicht/grosse--forschlitlitlichlichlichlich (ableung-ach-hodgkin-lymphom- therapy/), BRECADD is better than the previous standard ebeacopp, without negative influence.

In the extensive HD21 study, more than 1,500 participants in 233 centers in nine countries received one of two different forms of therapy. A look at the results that were recently published in the renowned specialist journal "The Lancet Oncology" is promising: three years after the therapy has been completed, 95 percent of women and 86 percent of men in the BRECADD group had normal hormone levels. For comparison: In the Ebeacopp Group it was only 73 percent of women and 40 percent of men. This shows the clear advantage of Brecadd treatment in relation to hormonal health and the chances of a later family start-up.

pregnancies and biological paternity in the upswing

The study also documents a significant increase in the number of pregnancies and births after treatment with Brecadd. This is particularly gratifying for men because they have a higher chance of biological paternity. Dr. Justin Ferdinandus and Dr. Karolin Behringer, who are significantly involved in the study, underline the importance of Brecadd not only for the healing rate, but also for the opportunity to start a family later.

But what happens to fertility in patients who rely on chemotherapy? As an evaluation shows, treatments against Hodgkin lymphoma have the desired healing success in about 80 % of the patients, but the side effects must continue to be discussed. According to pmc.ncbi.nlm.nih.gov, the risk of secondary infertility is a central topic that requires interdisciplinary dialogues between hematologists and chirurges. Chemotherapy in particular can affect the pool of primordial follicles in the ovaries, which can lead to premature ovarian failure.

New ways to preserve fertility

The challenges in the field of fertility are great. For women who are over 30 years old, the risk of complications increases significantly. In men, on the other hand, the spermatogonia memory remains constant, which fertility keeps relatively stable even in later years of life. However, the use of alkylating agents during therapy significantly increases the risk of infertility. Therefore, it is all the more important to develop innovative methods to preserve fertility, such as the cryooconservation of egg cells and ovarian tissue. These approaches are promising, but are still in the test phase.

The results of these studies should not only provide discussion material in medical specialist circles, but also offer encouraging perspectives for many affected and their relatives. Innovative treatment approaches show that it is quite possible to improve the quality of life and at the same time to adhere to future family planning. These developments are a step in the right direction and raise hopes for a more light future.